John Ross Named Executive Vice President at Metrics Inc.

He brings 20 years experience in contract pharma development and manufacturing operations   

GREENVILLE, N.C. – John S. Ross has been appointed executive vice president at Metrics Inc.

In his new role, Ross is responsible for managing and expanding Metrics’ fee-for-service operations. The company’s comprehensive contract services include pharmaceutical oral dose formulation development with dedicated suites for potent product handling; clinical trial materials manufacturing; analytical testing method development and validation; stability studies; and other laboratory support services.

His 20 years of progressive managerial experience include serving as chief operating officer and leading U.S. and Canadian operations at CPL, a contract manufacturing organization for liquid and semi-solid pharmaceutical products headquartered in Canada.

“John has a proven track record of delivering strong business performance while ensuring operational excellence and quality compliance with regulatory agencies worldwide,” said Stefan Cross, president of Mayne Pharma USA. “Metrics has, quite rightfully, earned a positive reputation for its thoughtful science and strong client relationships. John will help strengthen those partnerships to the benefit of all involved.”

Ross earned his MBA from the Ivey School of Business at the University of Western Ontario, from which he also received a bachelor’s of science degree in math and statistics.

Metrics Inc. is a full-service global pharmaceutical development and manufacturing organization serving clients worldwide. We deliver proven scientific and operational excellence for solid oral dosage forms.

Our areas of expertise include quality first-time-in-man (FTIM) formulations; clinical trial materials (CTM) manufacturing for Phases I, II and III; and raw material analytical support including elemental and trace metals and process validation services leading to commercial scale manufacturing.

Metrics’ technical capabilities include highly potent, cytotoxic and unstable compounds, Schedule II-V controlled substances, and products with poor bioequivalence, for which we offer an impressive proprietary portfolio of advanced delivery methods.  In the past five years, Metrics has conducted more than 75 first-time-in-man studies while producing 700-plus batches of clinical trial materials.

Our work supports investigational new drug (IND), new drug (NDA) and abbreviated new drug (ANDA) submissions worldwide on behalf of clients ranging from internationally renowned corporations to small virtual companies. Based in Greenville, N.C., Metrics Inc. proudly operates as a subsidiary of Mayne Pharma Group Limited. Visit  http://www.metricsinc.com to learn more.

  • <<
  • >>